Skip to main content
. Author manuscript; available in PMC: 2015 Jul 15.
Published in final edited form as: Oncogene. 2014 Jan 27;34(3):373–383. doi: 10.1038/onc.2013.562

Figure 2. Mitogenic effect of Elafin is mediated through the MEK/ERK pathway.

Figure 2

A. Multiplex iTRAQ analysis of OVCAR8 phosphoproteome at baseline and 30 minutes after adding 600 nM of rElafin. Heatmap of 404 entries, cut-off > 2.5-fold. B. Analysis of pathways altered by adding rElafin using pathway Palette software. C. Expression profile of MAP Kinase phosphopeptides activated in OVCAR8 +/− rElafin. Red lines represent global thresholds based on a ± 2.5-fold change between OVCAR8 +/− rElafin. D. Relative levels of phosphorylation of serine/threonine and receptor tyrosine kinases were determined in whole cells extracts (WCE) from OVCAR8 cells at baseline, then 10 and 60 minutes after stimulation with 300 nM of rElafin. E. Western blot analysis of pERK1/2, ERK1/2, pAKT and AKT in OVCAR8 WCE at baseline, then 10, 30, 60, 120, and 300 minutes after stimulation with 300 nM of rElafin.